Invitrogen

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™

Advanced Verification

This Antibody was verified by Knockdown to ensure that the antibody binds to the antigen stated.

11 Published Figures

13 References

View all (59) TRAIL-R2 (DR5) antibodies

Datasheet

Protocols

Questions & Answers

Datasheet

Protocols

Questions & Answers

CD262 (DR5) Antibody in Immunocytochemistry (ICC/IF)

FIGURE: 1 / 15

CD262 (DR5) Antibody (14-9908-82) in ICC/IF

Knockdown of CD262 (DR5) was achieved by transfecting MDA-MB-231 cells with CD262 (DR5) specific siRNA (Silencer® select Product # s16756). Immunofluorescence analysis was performed using untransfected MDA-MB-231 cells (panels a, d), transfected with non-specific scrambled siRNA (panels b,e) and transfected with CD262 (DR5) specific siRNAs (panel c,f). Cells were fixed, permeabilized, and probed with CD262 ... View More

CD262 (DR5) Antibody in Flow Cytometry (Flow)

CD262 (DR5) Antibody in Immunocytochemistry, Flow Cytometry (ICC/IF, Flow)

CD262 (DR5) Antibody in Western Blot, Flow Cytometry (WB, Flow)

CD262 (DR5) Antibody in Western Blot (WB)

CD262 (DR5) Antibody in Radioimmune assays (RIA)

Product Image Gallery

Product Details

14-9908-82

Applications

Tested Dilution

Publications

Western Blot (WB)

View 2 publications 2 publications

Immunocytochemistry (ICC/IF)

5 µg/mL

View 1 publication 1 publication

Flow Cytometry (Flow)

1 µg/test

View 9 publications 9 publications

Radioimmune Assays (RIA)

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

DJR2-4 (7-8)

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.2

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_468592

Product Specific Information

Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells.

Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis.

Applications Tested: The DJR2-4 (a.k.a. 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells. This can be used at less than or equal to 1 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.

Scientific reports

An Y,Jeon J,Sun L,Derakhshan A,Chen J,Carlson S,Cheng H,Silvin C,Yang X,Van Waes C,Chen Z

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Thu Mar 18 00:00:00 EDT 2021

RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.

Cell death & disease

Khawaja H,Campbell A,Roberts JZ,Javadi A,O'Reilly P,McArt D,Allen WL,Majkut J,Rehm M,Bardelli A,Di Nicolantonio F,Scott CJ,Kennedy R,Vitale N,Harrison T,Sansom OJ,Longley DB,Evergren E,Van Schaeybroeck S

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Thu Oct 29 00:00:00 EDT 2020

YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells.

Cell death & disease

Wang Y,Guo S,Li D,Tang Y,Li L,Su L,Liu X

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Fri Apr 17 00:00:00 EDT 2020

YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells.

Cell death & disease

Wang Y,Guo S,Li D,Tang Y,Li L,Su L,Liu X

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Fri Apr 17 00:00:00 EDT 2020

Antitumor Effect of Periplocin in TRAIL-Resistant gastric cancer cells via upregulation of death receptor through activating ERK1/2-EGR1 pathway.

Molecular carcinogenesis

Zhao LM,Li L,Huang Y,Han LJ,Li D,Huo BJ,Dai SL,Xu LY,Zhan Q,Shan BE

14-9908-82 was used in Flow cytometry/Cell sorting to imply that Periplocin might act as a sensitizer of TRAIL and could be a potential strategy for the treatment of GC.

Sat Jun 01 00:00:00 EDT 2019

Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.

Cell death discovery

Carr RM,Qiao G,Qin J,Jayaraman S,Prabhakar BS,Maker AV

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Western Blot

Tue Sep 20 00:00:00 EDT 2016

Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.

Clinical cancer research : an official journal of the American Association for Cancer Research

Liu Y,Hawkins OE,Vilgelm AE,Pawlikowski JS,Ecsedy JA,Sosman JA,Kelley MC,Richmond A

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Radioimmune Assays

Tue Dec 01 00:00:00 EST 2015

TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.

PloS one

Chandrasekaran S,Marshall JR,Messing JA,Hsu JW,King MR

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Thu Dec 24 00:00:00 EST 2015

TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.

PloS one

Chandrasekaran S,Marshall JR,Messing JA,Hsu JW,King MR

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Thu Dec 24 00:00:00 EST 2015

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.

PloS one

Turner A,Li LC,Pilli T,Qian L,Wiley EL,Setty S,Christov K,Ganesh L,Maker AV,Li P,Kanteti P,Das Gupta TK,Prabhakar BS

14-9908 was used in Flow cytometry/Cell sorting to investigate how strategies to decrease MADD expression in breast cancer may be utilised to increase tumour cell sensitivity to TRAIL and doxorubicin induced apoptosis.

Wed Aug 28 00:00:00 EDT 2013

Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.

Neoplasia (New York, N.Y.)

Woldemichael GM,Turbyville TJ,Vasselli JR,Linehan WM,McMahon JB

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Wed Aug 01 00:00:00 EDT 2012

A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.

Proceedings of the National Academy of Sciences of the United States of America

Dompe N,Rivers CS,Li L,Cordes S,Schwickart M,Punnoose EA,Amler L,Seshagiri S,Tang J,Modrusan Z,Davis DP

Published figure using CD262 (DR5) monoclonal antibody (Product # 14-9908-82) in Flow Cytometry

Tue Oct 25 00:00:00 EDT 2011

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.

Cancer research

Earel JK,VanOosten RL,Griffith TS

Sun Jan 01 00:00:00 EST 2006

Bioinformatics

Protein Aliases: apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; Death receptor 5; dr-5; Fas-like protein; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF-related apoptosis-inducing ligand receptor 2; TRAIL receptor 2; Tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9

View more View less

Gene Aliases: CD262; DR5; KILLER; KILLER/DR5; TNFRSF10B; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; UNQ160/PRO186; ZTNFR9

View more View less

UniProt ID: (Human) O14763

View more View less

Entrez Gene ID: (Human) 8795

View more View less

Function(s)

receptor activity tumor necrosis factor-activated receptor activity protein binding TRAIL binding transmembrane signal receptor

Process(es)

apoptotic process activation of cysteine-type endopeptidase activity involved in apoptotic process inflammatory response immune response cell surface receptor signaling pathway activation of NF-kappaB-inducing kinase activity multicellular organism development extrinsic apoptotic signaling pathway via death domain receptors response to lipopolysaccharide tumor necrosis factor-mediated signaling pathway response to endoplasmic reticulum stress regulation of cell proliferation regulation of apoptotic process positive regulation of I-kappaB kinase/NF-kappaB signaling intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress cellular response to mechanical stimulus activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway regulation of extrinsic apoptotic signaling pathway via death domain receptors negative regulation of extrinsic apoptotic signaling pathway via death domain receptors

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™

CD262 (DR5) Antibody (14-9908-82) in ICC/IF

Product Details

14-9908-82

Western Blot (WB)

Immunocytochemistry (ICC/IF)

Flow Cytometry (Flow)

Radioimmune Assays (RIA)

Species Reactivity

Published species

Host/Isotype

Class

Type

Clone

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!